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A LOOK AHEAD AT TRANSPLANTATION 
---------------------------------------------------------
THOMAS E. STARZL, M.D.'" 
IN THE FOLLOWING REMARKS, I am go-
ing to concentrate on some specific problems 
which have not been solved or upon which 
more research effort needs to be invested. The 
first concerns Organ Preservation. 
There is no way that widespread and effi-
cient utilization of human organ homo grafts 
will ever be possible without major new de-
velopments in organ preservation which will 
allow banking for weeks or months. Progress 
in this direction has been relatively minor. 
Thanks to the work of Lillehei, Humphries, 
Marchioro, Brettschneider, Belzer, and many 
others it has become possible to keep vital 
organs in good condition for a number of 
hours or even for as long as 2 or 3 days. In 
general, the techniques have either involved 
cooling or perfusion. In addition, hyberbaric 
oxygenation or the use of metabolic inhibitors 
has been employed as adjuvant measures. 
In Fig. 1 is shown an example of the kind 
of device that can be built for organ conserva-
tion, this being the preservation unit devel-
" oped by Brettschneider for livers. The excised 
organ is protected by three means. It is per-
fused through the portal vein and hepatic 
. artery, cooled at 4 DC, and kept in a hyperbaric 
*Talk delivered at The Association for Academic 
Surgery Meeting in Boston, Massachusetts on Nov. 
21, 1969. 
From the Department of Surgery, University of 
Colorado School of Medicine, and the Veterans Ad-
ministration Hospital, Denver, Colorado. 
Supported by United States Public Health Service 
Grants AM-06344, AM-07772, FR-00051, AI-04152, 
FR-04152, FR-00069, AM-12148, and AI-AM-08898. 
oxygen environment. Conceivably, one could 
add to the perfusate a variety of metabolic 
inhibitors such as those reported by Webb, by 
Fonkalsrud, and others. 
In spite of the importance of these efforts, 
they have not held much promise of permit-
ting long-term storage, and it must be con-
ceded that there has been less progress toward 
organ banking than in any other aspect of 
transplantation. This fact has been recognized 
by the Surgical Study sections of the NIH as 
well as by the Transplantation Snbcommittee 
of the National Research Council. In a sense, 
the NIH and National Research Council com-
mittees are involved in long-term scientific 
planning. This fact is worth emphasizing to a 
group of young academic surgeons for at least 
one very practical reason. Presently, research 
grants are generally hard to obtain but at the 
same time significant sums of money are still 
available to support truly innovative proposals 
in the field of preservation. It will, of course, 
be necessary to have original ideas about how 
either solid state or perfusion techniques can 
be applied rather than submitting protocols 
that have already been thoroughly tested. The 
thought that I would like to leave is that new 
and old workers with fresh ideas about organ 
preservation can reasonably expect to receive 
tangible encouragement in the form of money. 
The next topic I would like to touch on is 
Histocompatibility Typing. The last 5 years 
has been a time of intense activity of a small 
but devoted group of tissue typers in the 
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Fig. 1. Preservation unit. The perfusion pumps are located outside the hyperbaric chamber; the organ 
receptacle, the oxygenator, and the venous reservoir are inside. The various chamber inlets permit sam-
pling of the perfusate, gas sterilization, and oxygen delivery and removal. The temperature is electron-
ically controlled. (By permission of Surg. Gynec. Obstet. 126:26.3, 1968). 
United States and Europe. These men and 
women have developed methods to identify 
antigens in lymphocytes and other tissues. In 
related cases, particularly involving siblings, 
it has been repeatedly demonstrated that a 
good tissue match is a highly favorable prog-
nostic condition and that the converse is true 
if the match is a poor one. With more distant 
relationships, the correlation between tissue 
matching and the clinical outcome may be 
tenuous at best and in the present state of the 
art, such correlations may not exist at all with 
cadaveric transplantation. It is particularly 
important in 1969 to realize this since donors 
for most extrarenal organs must come from 
292 
nonrelated cadaveric sources. Our own con-
fidence in tissue matching with serologic tech-
niques is so limited in nonrelated cases that 
we do not anticipate a good result simply be-
cause of a fine match, nor do we refrain from 
using cadaveric organs on the basis of a bad 
match. This point of view can be more easily 
illustrated than described. . 
Shown in Fig. 2 is a human orthotopiC liver 
homograft at 68 days. This organ was A 
matched despite which it was inexorably re-
jected in a little more than 2 months. The 
rejected liver was removed and replaced with 
a homograft which had frank mismatches in 
groups HLA 5 and 6. The second, or D-
• I 
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Fig. 2. A rejecting orthotopic liver homograft in a patient who was said to have an A histocompatibil-
ity match with the donor. The protruding homograft as it was seen when the transverse abdominal inci-
sion was reopened. Note the enormous swelling, as well as the heterogeneous appearance of its surface. 
This liver was removed at the same operation and replaced with a second homograft which came from 
a donor with a D match. Although the second organ also underwent a severe rejection, it supported life 
for an additional year. 
matched organ then supported life for more 
than a year. The best result we have obtained 
in our liver series was in the reCipient of a 
hepatic homograft that was mismatched in 
four groups including HLA 2, 3, and 7. The 
recipient of this D-matched kidney had two 
rather minor rejection episodes early in his 
convalescence (Fig. 3) but he has an excellent 
result with completely normal liver function 
now 1}2 years after operation. 
For reasons pOinted out by the tissue typers 
themselves, the measurement of histocompati-
bility between unrelated individuals is very 
imprecise and incomplete using the serologic 
methods. It is probable that a direct cross-
match technique, such as the mixed lympho-
cyte culture method of Hirschhorn and Bach, 
would be much more discriminating. How-
ever, the Hirschhorn-Bach approach requires 
the better part of a week to be completed, a 
time that is much too long to permit practical 
application in most cadaveric cases at the 
present time. However, it is also obvious that 
a major advance in organ banking would per-
mit the application of such direct measures of 
histocompatibility. Thus, the research on 
organ preservation that I have already men-
tioned would not only cut the waste of cada-
veric organs that is inevitable today, but it 
would also allow the use of more predictive 
techniques of tissue typing. 
Of course, the need for tissue banks would 
be reduced if animal organs could be em-
ployed. \iVhen tissues and organs are trans-
planted across a species barrier this is desig-
nated I-I eterotransplantation or Xenotrans-
plantation. The terms are descriptive but im-
precise since the kind of rejection that may 
follow may be no different but only more 
severe than after many homotransplantations. 
On the other hand, a xenograft may be repu-
diated within a matter of minutes depending 
293 
gli~kAi OF SURGICAL RESEARCH VOL. 10 No.6, JUNE 1970 
SGOT 
( IU.) 
ALKALINE 
PHOSPHATASE 
( IU.) 
12 
8 
OT 19 4 Y.O. d' 
14.3 -+180 kg: 
SERUM PROTEIN 
(g/IOO ml) 
TOTAL-
ALBUMIN -----
Y GLOBULIN 4 o -DDD~I- /- -K:-~K- - - - .. ~K~K~K~-~ .. ~K~K:K::~K~- ~K~K= -K~:-~~K=K~K~ ~K- :K:K~ .. :K~K~:K~-~K=~~:~K~K:=-~:D~K~ .. --.................... -. 
BILIRUBIN 
(mg/IOOml) 
TOTAL--
CONJUGATED" •••• 
AZATHIOPRINE 
(mg) 
10 REJECTION 
5 
PREDNISONE 
(mg) 
ALG .120" =~!l=:;::::~~~~:;::::;;::;C::D::;;=;:::;;;;~~~~::::;~ ~ EVERY THIRD DAY 'TWICE A WEEK 
20 ~ ~ ~ w ro 5 6 7 8 
TIME IN DAYS TIME IN MONTHS 
Fig. 3. A 4-year-old child with intrahepatic biliary atresia who was treated with orthotopic liver trans-
plantation. The histocompatibility match with the donor was classified as D· (See text). A very tran-
sient rejection occurred after 1 month. This underwent almost immediate and complete remission. A late 
rejection which began on postoperative Day 72 was also easily controlled. Note the change in time scale 
after 4 months. The patient still has perfect liver function after 18 months. He is still receiving ALG. 
The normal enzyme values in international units at this age are: alkaline phosphatase, 57-151; SGOT, 
3-27; and SGPT, 2-30. 
upon the kind of donor-rccipient animal com-
bination. If hyperacute rejection occurs, it can 
usually be shown that preformed heterospeci-
fie antibodies are present in the recipient and 
that these have a high aVidity for cells of the 
donor species. 
The thought that animal organs might be 
clinically useful was generally conceded to be 
totally unfounded until the trials of chimpan-
zee-to-man renal heterografts performed by 
Reemtsma in 1963. That experience and a 
similar though less satisfactory one with ba-
boon kidneys, indicated that even then hetero-
transplantation was almost, but not quite, 
good enough to have some real utility. Subse-
quently, many laboratories have contributed 
important details to an understanding of het-
erograft rejection and how this process might 
be controlled. There will be time to refer to 
only a few of these shldies. 
The first serious attempt to define the hy-
peracute rejection seen in unfavorable donor-
recipient combinations was by Clark and 
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Gewurz and their associates at the Universitv 
of Minnesota. They showed that rabbit kid-
neys transplanted to dogs cleared formed 
blood elements as well as hemolysins, he mag-
glutinins, and complement. They stressed the 
role of the preformed host antibodies in caus-
ing sudden devascularization of the trans-
plants. With less divergent species, the role 
of immunoglobulins in the rejection process 
is less important, although still probably sig-
nificant. In a variety of species it has been 
found that techniques to deplete these anti-
bodies or complement can prolong life of sub-
sequently placed heterografts. 
It is probable that the paper of Lance and 
Medawar published in The Lancet in 1968 
will be regarded as a landmark in heterotrans-
plantation. Lance and Medawar were able to 
transplant skin from humans, rabbits, guinea 
pigs, and rats to ALS-treated CBA mice and 
achieve survival of the skin transplants for 
several months. In a sense, this work was con-
firmatory of earlier observations of Monaco 
and in tum it has been confirmed by other 
workers including Cerilli of Ohio. Finally, at 
the Surgical Forum last month we were told 
. by Gunnarson and Najarian that pig kidneys 
transplanted to goats survived and functioned 
for as long as 2 weeks in recipients treated 
with ALG and cytosine arabinoside. I have 
mentioned only a few straws in the wind that 
hold more than a hope that heterotransplanta-
tion is more than a Buck Rogers concept for 
the academic surgeon. 
Now let me tum to the question of Graft 
Acceptance. About 10 years ago it was noted 
by Zukoski and by Pierce and Varco that im-
munosuppressive therapy could sometimes be 
stopped after canine renal transplantation 
with very long subsequent functional survival 
of the transplanted kidneys. In these first re-
ports, the postoperative therapy had been with 
6-mercaptopurine but it has since been dem-
onstrated that the exact nature of initial treat-
ment is not critical to achieve this result. Thus, 
examples of "graft acceptance" have been re-
ported with azathioprine, ALS, ALG, predni-
sone ,and even total body irradiation. Shown 
in Fig. 4 is a dog which received an unrelated 
orthotopic liver homograft in March of 1964 
and which was treated for 4 months with aza-
thioprine. Therapy was then stopped and the 
animal is still well more than a half a canine 
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lifetime later. We have dogs in our laboratory 
which have been off the therapy for as long as 
6Y2 years after renal transplantation under the 
same circumstances. 
The unanswered question in experiments 
like these is how such transplants have come 
to acquire their privileged status. It is prob-
able that more than one immunologic path-
way is involved. A classical possibility is that 
the continuous presence of a transplanted 
organ in a host being treated with immuno-
suppressive therapy leads to a selective loss 
of responsiveness to the antigens of the homo-
graft (Fig. 5). The term for this would be 
"tolerance." That antigen stimulation plus im-
munosuppression can lead to this state of 
narrow-range tolerance has not been seriously 
questioned since Schwartz first called atten-
tion to this possibility in 1959. In this concept 
it is suggested that a specific fraction of the 
lymphocyte population is stimulated to action 
and that these sensitized cells are therebv 
rendered more susceptible to the killing effe~t 
of the immunosuppressive agent than the rest 
of the lymphocyte population. There is evi-
dence that I do not have time to review here 
that at least partial tolerance is often acci-
dentally produced in the course of clinical 
transplantation. From animal work, it would 
be expected that thymectomy would facilitate 
Fig. 4. A dog whose liver was replaced with the liver of a nonrelated mongrel donor in March 1964. 
Immunosuppressive therapy was with azathioprine alone. This drug was stopped after 4 months and the 
animal is in perfect condition more than 5 years later. 
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Fig. 5. Hypothetical mechanisms by which nonspecific immunosuppression may lead to selective abro-
gation of the host immune response. Special susceptibility to these agents of a fraction of the lymphoid 
population could lead to exhaustion of a clone and, hence, tolerance. Since maintenance of such cell 
lines even in adult life is apparently thymus dependent in experimental animals, thymectomy would be 
expected to aid the process; this appears to be true in rodents, but such an effect of thymus remova1 
has not been detected in dogs or humans. A possible protective role is also shown in immunoglobulins 
elaborated by the replicating cells. Conceivably the antibodies could act either at the site of the antigen 
(enhancement) or by affecting the macrophage processing of the antigen. See text for discussion. 
this process by removing the source of rein-
forcements to the cell line under attack 
(Fig. 5). 
However, other lines of evidence have 
strongly indicated that tolerance is not the 
only mechanism by which graft acceptance is 
achieved. If tolerance were present, it should 
then be possible to transplant tissues and or-
gans from the same donor to the recipient and 
have these new tissues accepted. This is very 
often not the case as was demonstrated by 
Woodruff 15 years ago with thyroid, and more 
recently by Cannon and Longmire with skin 
and by Murray with kidneys. Lately there has 
been much speculation that such primary 
grafts achieve their relative state of invulnera-
bility partly by a process known as enchance-
ment. Here the hypothesis is that antigraft 
antibodies are produced in response to the 
homograft antigens and that they return to 
coat or protect the transplant by some means 
which is not understood (Fig. 5). 
The attempts to understand graft accep-
tance have been prompted by much more 
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than idle curiosity since it would be highly 
desirable to meet the conditions of graft ac-
ceptance before arrival of the homo grafts 
rather than hoping to achieve these conditions 
accidentally secondary to the actual trans-
plantation. If this could be accomplished in 
advance, rejection could be prevented with 
far less crippling of the immune apparatus in 
the postoperative period. 
At this year's Surgical Forum there were 
several papers, including those by Raju, by 
Yussman, and by Holl-Allen and their asso-
ciates, all concerned with the questions I have 
just posed. More importantly, Stuart and his 
associates at the University of Chicago have 
paSSively immunized rat recipients with speci-
fic antigraft antibodies and have obtained pro-
longed function of rat renal transplants. 
When the use of enhancing antibodies was 
combined with donor-specific antigen pre-
treatment, homo grafts functioned for 18 
months or longer in the presence of a strong 
histocompatibility barrier despite the fact that 
the recipients sometimes did not have a loss 
of immunologic memory for the donor strain 
tissues. Stuart has suggested that both toler-
ance and enhancement may have played a 
. role in the striking graft protection observed 
in his experiments without using any immuno-
suppression at all. 
I would like to close by adding a few com-
ments about Clinical Transplantation. There 
is no point in spending time on renal trans-
plantation since this subject is undoubtedly 
well known to all of you. However, in pass-
ing, it is worth noting that recipients of vital 
organs other than the kidney have also had a 
meaningful extension of life. The longest sur-
vivor after liver transplantation is still alive 
after 22 months. To date the maximum follow-
up of a heart recipient has been of Dr. Philip 
Blaiberg, who lived for 19 months. Lillehei 
and his associates have had recent encourag-
ing experience with combined renal and pan-
creatic transplantation. I am told that two of 
their patients who were operated upon about 
6 months ago have been discharged from the 
hospital and that their insulin requirements 
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are minimal or absent. Professor Derom of 
Ghent, Belgium, had a patient who lived 10 
months after lung transplantation before dying 
of slow rejection . 
In summary, I apologize to this group for 
having talked more about what should be 
new in transplantation than what is new in 
this field. I am going to justify having done 
this in the following way. Each generation 
contains its pessimists who regret having been 
born too late, at a time when the ultimate in 
discovery and progress has already been 
achieved. Surgery has been no exception. Ad-
vances in surgery have often been preceded 
by dire predictions of their impossibility, or 
worse, followed by opinions that the last 
frontier has been breached, leaving only small 
details for future cultivation. Of course, this 
attitude has no place in life and it certainly 
does not in the surgical discipline of trans-
plantation, where almost certainly the most 
important advances are yet to be made, and 
I hope, by the members of this young and 
vigorous academic surgical society. 
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